57 (PB045): Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
Year: 2024
Type: article
Source: European Journal of Cancer
Authors: M. Hojgaard, T.A. Yap, E.K. Lee, M.C. Weiss, S. Lheureux, F. Simpkins, P. LoRusso, B.A. Carneiro, R.H. Moy, E. Aguado-Fraile, S. Sethuraman, I. Soria-Bretones, Y. Liu, X. Sun, N. Hawkey, P. Basciano, T.J. Unger, E.S. Bacqué, A. Schram
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4403749184